Novartis MS drug remibrutinib seen advantaged on liver safety
Citi analysts said Novartis’s late-stage multiple sclerosis studies for remibrutinib reported no liver-safety signals, potentially differentiating it from a Roche rival drug based on safety profile.
Novartis's new multiple sclerosis drug might stand apart from a rival product Roche Holding is developing due to its safety profile, Citi analysts say in a research note.
Novartis reported no liver-safety signals in its late-stage studies for its remibrutinib drug in multiple sclerosis, while Roche…